Mental Health and Neuroscience
Addressing an epidemic
Mental health disorders now constitute a national crisis. These conditions rank at the top for both high unmet needs and total healthcare spending. Yet, despite increased clinical development of new treatments, high quality insights from research to enable market adoption, broaden payer coverage, and personalize care are lacking or have been difficult to attain.
Mental health is complex. Accessing data shouldn’t be.
Understanding the complexities of these diseases and how varying factors affect access to treatments and care all shape how this specialty area is unique. It is exactly those same unique characteristics that drive our focus on bringing a dynamic new approach to mental health and neuroscience data to healthcare stakeholders.
Meet the largest Mental Health & Neuroscience data network in the U.S.
A comprehensive view of the patient journey from clinical development to the clinic
Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to empower your programs shouldn’t be. That’s why we built the largest mental health and neuroscience network in the U.S — rich with longitudinal clinical data and ready for addressing your most urgent questions.
2,500+Specialty practices |
9,000+Specialty clinicians |
Mental Health• ADHD |
Neuroscience• Alzheimer’s Disease |
Sample conditions*
Every condition presents its own unique challenges and opportunities. Select one of our sample datasets above to explore some of the features.
Major Depressive Disorder patients with deep clinical data
7 yrs
Mean follow-up
Schizophrenia patients with deep clinical data
4.3 yrs
Mean follow-up
Bipolar patients with deep clinical data
4 yrs
Mean follow-up
MS patients with deep clinical data
7.6 yrs
Mean follow-up
*Data counts as of Q2 2024 ©OM1 Mental Health & Neurosciences Specialty Area
From evidence to insights
USE CASE
Burden of illness – mental health disorders in MS patients
Identify the population of MS patients with comorbid mental health conditions and understand unmet mental health intervention and impact on disease activity.
LEARN MORE
USE CASE
Evaluate treatment response and utilization in schizophrenia patients
Evaluate the side-effects (including weight gain and other risk factors) and costs associated with use of second generation antipsychotics.
LEARN MORE
USE CASE
Predict treatment resistance for depression
Predict which Treatment Resistant Depression (TRD) patients are at higher risk of excess resource utilization, using pre-treatment information to inform case management.
LEARN MORE
Meet our mental health expert
Dr. Carl Marci is the Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. Previously, he was Chief Psychiatrist and Chief Medical Officer at several venture backed health and technology companies.
Dr. Marci is board certified and is part-time staff at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School, he completed two NIH Fellowships in neuroscience and has published numerous articles in peer-review science journals. He holds seven patents and is author of a forthcoming book on the impact of technology on the brain.
Dr. Marci is a graduate of Columbia University and Oxford University where he was a Rhodes Scholar. He then went to Harvard Medical School and graduated with honors; he is also the former Director of Social Neuroscience at Massachusetts General Hospital.
Award-Winning Research Team
Our team of award-winning researchers have authored hundreds of publications, including scientific posters, articles in peer-reviewed journals, white papers, and books.